DDInter1476 DDInter1331
Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50%. The precise function of these receptors has not been established. The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3†,5†-adenosine monophosphate (c-
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated symptoms such as shortness of breath, cough, and sputum production. Single doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing. A once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period. Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma.
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Pirbuterol {u} (Compound) resembles {v} (Compound) Nadolol
Nadolol {u} may lead to a major life threatening interaction when taken with {v} Olodaterol
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Olodaterol
Pirbuterol {u} (Compound) resembles {v} (Compound) Epinephrine
Epinephrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methylphenidate
Methylphenidate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Pirbuterol {u} (Compound) resembles {v} (Compound) Bupranolol
Bupranolol {u} (Compound) resembles {v} (Compound) Penbutolol
Penbutolol {u} may lead to a major life threatening interaction when taken with {v} Olodaterol
Pirbuterol {u} (Compound) resembles {v} (Compound) Nadolol
Nadolol {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Fingolimod {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norfloxacin
Norfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Pirbuterol {u} (Compound) resembles {v} (Compound) Terbutaline
Terbutaline {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Pirbuterol {u} (Compound) resembles {v} (Compound) Bupranolol
Bupranolol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Pirbuterol {u} (Compound) resembles {v} (Compound) Bupranolol
Bupranolol {u} (Compound) resembles {v} (Compound) Nadolol
Nadolol {u} may lead to a major life threatening interaction when taken with {v} Olodaterol
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Pirbuterol (Compound) resembles Nadolol (Compound) and Nadolol may lead to a major life threatening interaction when taken with Olodaterol
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Pirbuterol (Compound) resembles Epinephrine (Compound) and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Methylphenidate and Methylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Pirbuterol (Compound) resembles Bupranolol (Compound) and Bupranolol (Compound) resembles Penbutolol (Compound) and Penbutolol may lead to a major life threatening interaction when taken with Olodaterol
Pirbuterol (Compound) resembles Nadolol (Compound) and Nadolol may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Pirbuterol (Compound) resembles Terbutaline (Compound) and Terbutaline (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Pirbuterol (Compound) resembles Bupranolol (Compound) and Bupranolol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Pirbuterol (Compound) resembles Bupranolol (Compound) and Bupranolol (Compound) resembles Nadolol (Compound) and Nadolol may lead to a major life threatening interaction when taken with Olodaterol